Overview
- The international review published June 17 in The Lancet Psychiatry analysed policy changes from 2000–2025 and found that large commercial, for‑profit markets in places such as parts of the United States and Canada are associated with higher product potency, greater sales and more daily users.
- Researchers report that commercialised markets correlate with rising rates of cannabis use disorder and increased psychiatric admissions, including more hospital visits for psychosis in jurisdictions with expanded retail and marketing.
- The study found that decriminalisation or tightly regulated legalisation models, such as Uruguay’s pharmacy and club system, show little evidence of increasing overall population use.
- Clinical-trial evidence for medical cannabinoids was limited across 54 trials, with small benefits for sleep and some withdrawal symptoms but no meaningful support for treating most psychiatric disorders and a warning that poorly regulated medical access can increase harm.
- Authors call for stronger policy tools—examples include potency limits, restricted retail models, co‑operative or pharmacy distribution, and tax revenue reinvestment—along with broader international monitoring and more research outside North America.